AbbVie Inc. (ABBV)
AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?
AbbVie's NYSE: ABBV share price has been under pressure due to rising costs and concerns that its post-Humira days won't be as robust. However, the stock price decline put the market in a position to trigger a trend-following signal, which happened after its Q1 earnings results.
AbbVie (ABBV) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ABBV Seeks FDA Nod for Rinvoq Label Expansion in Alopecia Areata
AbbVie files for the FDA approval of Rinvoq in alopecia areata, backed by phase III data showing strong hair regrowth and durable results.
Big Boosts to Econ Growth from AI Investment, Inventories & More
For once, there is something even bigger than the Strait of Hormuz affecting investors' attitudes this morning.
AbbVie (ABBV) Tops Q1 Earnings and Revenue Estimates
AbbVie (ABBV) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.62 per share. This compares to earnings of $2.46 per share a year ago.
AbbVie Raises FY Guidance on Immunology, Neuroscience Growth
AbbVie raised its full-year adjusted earnings guidance and reported higher first-quarter revenue, boosted by growth in its immunology and neuroscience portfolios.
Will These 5 Drug Bigwigs Surpass Q1 Earnings Forecasts?
LLY, MRK, ABBV, BMY and BIIB are set to report this week as recent beats and key drug demand set up a pivotal Q1 earnings test for pharma giants.
Best Dividend Kings: April 2026
Dividend Kings are outperforming SPY year-to-date, with 36 of 58 beating the index with an average gain of 7.03% versus SPY's 4.18%. Twenty-seven Dividend Kings are both potentially undervalued and offer a long-term annualized expected return of at least 10%. Recent dividend increases among Kings have been modest, with the average 2026 dividend growth rate rising to 3.11%.
AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues
ABBV gets FDA CRL for TrenibotE tied to manufacturing issues. The company plans a full response in the coming months.
Insights Into AbbVie (ABBV) Q1: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
10 Dividend Growth Stocks: April 2025
I rank a selection of dividend growth stocks and present the top 10 stocks for consideration. Dividend growth stocks have dividend increase streaks of at least 5 years. To rank stocks, I do a quality assessment and sort candidates by quality scores. My new quality scoring system rates dividend stocks on a 10-point scale across 9 weighted factors. Each factor blends qualitative signals and quantitative metrics.
These 5 Stocks Pay You Even When You're Sleeping
Market volatility in 2026 has reminded investors that earned income alone is fragile.
